Zurueck zur Suche

Reporte zur Charge UJN04AA

Verknuepft ueber VAERS_ID mit VAERSDATA, Vax und Symptoms

5Reporte angezeigt
0Todesfaelle
0Hospitalisiert
0Lebensbedrohlich
0Bleibende Schaeden
CA 5

VAERS 2440299

SANOFI PASTEUR · INFLUENZA (SEASONAL) (FLUZONE HIGH-DOSE QUADRIVALENT) · Charge UJN04AA

gering
Staat
CA
Alter
48,0
Geschlecht
F
Eingang
12.09.2022
Impfdatum
30.08.2022
Beginn
30.08.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
OT / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
No adverse event Product use issue

Symptomtext

48 year old patient administered fluzone high-dose vaccine, with no reported adverse event; Initial information received on 31-Aug-2022 regarding an unsolicited valid non-serious case received from a pharmacist. This case involves a 48 years old female patient who was administered fluzone high-dose vaccine, with no reported adverse event while receiving vaccine INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE [FLUZONE HIGH-DOSE QUADRIVALENT]. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On 30-Aug-2022, the patient received 0.7 mL dose of suspect INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE (formulation, strength not reported; lot UJN04AA, expiry date: 30-Jun-2023) via intramuscular route in the deltoid nos for prophylactic immunization. On 30-Aug-2022, (latency: same day) the 48 year old patient administered fluzone high-dose vaccine, with no reported adverse event (product use issue) following the administration of INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE. Action taken was not applicable. At time of reporting, the outcome was Unknown for the event. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.; Sender's Comments: 01257338: 01258901: 01258901: 01258919: 01258920: US-SA-2022SA365119:01258924

Weitere VAERSDATA-Felder
Praegender Schweregrund
No adverse event
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2440298

SANOFI PASTEUR · INFLUENZA (SEASONAL) (FLUZONE HIGH-DOSE QUADRIVALENT) · Charge UJN04AA

gering
Staat
CA
Alter
30,0
Geschlecht
F
Eingang
12.09.2022
Impfdatum
30.08.2022
Beginn
30.08.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
OT / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Product administered to patient of inappropriate age

Symptomtext

they administered FLUZONE HD to employees that were not 65 and older with no reported adverse event; Related cases: US-SA-2022SA364394, US-SA-2022SA365006, US-SA-2022SA366945, US-SA-2022SA365883. Initial information received on 31-Aug-2022 regarding an unsolicited valid non-serious case received from a pharmacist. This case involves a 30 years old female patient who was administered INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE [FLUZONE HIGH-DOSE QUADRIVALENT] long with other employees that were not 65 and older with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On 30-Aug-2022, the patient received a 0.7 ml dose of suspect INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE (lot UJN04AA, 30-Jun-2023) via intramuscular route in the deltoid NOS as Immunization. On 30-Aug-2022 the patient developed a non-serious "they administered fluzone hd to employees that were not 65 and older with no reported adverse event" (product administered to patient of inappropriate age) following the administration of INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE. it was reported that Nurse reports that yesterday, they held an Employee Health Clinic and administered flu vaccines. She states that there was a "communication error" between staff, complicated by a failure to perform "triple checks". This resulted in 5 employees receiving FLUZONE HIGH-DOSE. No other vaccines were administered. QUADRIVALENT vaccine, though they were < 65 years-old. Action taken: not applicable. At time of reporting, the outcome was Unknown for the event. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.; Sender's Comments: US-SA-2022SA364394:01257338 US-SA-2022SA365006:01258901 US-SA-2022SA366945:01258919 US-SA-2022SA365883:01258924

Weitere VAERSDATA-Felder
Praegender Schweregrund
Product administered to patient of inappropriate age
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2440297

SANOFI PASTEUR · INFLUENZA (SEASONAL) (FLUZONE HIGH-DOSE QUADRIVALENT) · Charge UJN04AA

gering
Staat
CA
Alter
41,0
Geschlecht
F
Eingang
12.09.2022
Impfdatum
30.08.2022
Beginn
30.08.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
OT / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
No adverse event Product administered to patient of inappropriate age

Symptomtext

Patient under age 65 administered Fluzone HD in error no adverse event; Related cases: US-SA-2022SA364394, US-SA-2022SA365006, US-SA-2022SA365119, US-SA-2022SA365883. Initial information received on 31-Aug-2022 regarding an unsolicited valid non-serious case received from a pharmacist. This case involves a 41 years old female patient who was administered influenza quadrival A-B high dose HV vaccine [Fluzone High-Dose Quadrivalent] in error no adverse event. Patient is under age 65. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On 30-Aug-2022, the patient received a 0.7 ml dose of suspect influenza quadrival A-B high dose HV vaccine (formulation, strength: unknown) (lot UJN04AA, 30-Jun-2023) via intramuscular route in the deltoid NOS for immunization patient under age 65 administered fluzone hd in error no adverse event (product administered to patient of inappropriate age) (latency; Same day). Nurse reports that yesterday, they held an Employee Health Clinic and administered flu vaccines. She states that there was a "communication error" between staff, complicated by a failure to perform "triple checks". This resulted in 5 employees receiving FLUZONE HIGH-DOSE. No other vaccines were administered. QUADRIVALENT vaccine, though they were < 65 years-old. Action taken : not applicable. Outcome : Unknown. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.; Sender's Comments: US-SA-2022SA365119:01258919

Weitere VAERSDATA-Felder
Praegender Schweregrund
No adverse event
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2440296

SANOFI PASTEUR · INFLUENZA (SEASONAL) (FLUZONE HIGH-DOSE QUADRIVALENT) · Charge UJN04AA

gering
Staat
CA
Alter
36,0
Geschlecht
F
Eingang
12.09.2022
Impfdatum
30.08.2022
Beginn
30.08.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
OT / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
No adverse event Product administered to patient of inappropriate age

Symptomtext

Patient under age 65 administered Fluzone HD in error with no reported AE; Initial information received on 31-Aug-2022 regarding an unsolicited valid non-serious case received from a pharmacist. This case involves a 36 years old female patient who was under age 65 and was administered fluzone hd in error with no reported adverse event , after receiving vaccine INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE [FLUZONE HIGH-DOSE QUADRIVALENT]. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On 30-Aug-2022, the patient received a dose of suspect INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE (Strength: high dose) lot UJN04AA and expiration date: 30-Jun-2024 at a dose of 0.7ml via intramuscular route in the deltoid nos for immunization. On 30-Aug-2022 (Latency: same day), the patient was under age 65 and was administered fluzone hd in error with no reported ae (product administered to patient of inappropriate age) following the administration . Action taken:not applicable It was not reported if the patient received a corrective treatment for the event . Outcome: unknown This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.; Sender's Comments: 01257338: 01258919: 01258920: 01258924: US-SA-2022SA365119:01258901

Weitere VAERSDATA-Felder
Praegender Schweregrund
No adverse event
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2440290

SANOFI PASTEUR · INFLUENZA (SEASONAL) (FLUZONE HIGH-DOSE QUADRIVALENT) · Charge UJN04AA

gering
Staat
CA
Alter
28,0
Geschlecht
F
Eingang
12.09.2022
Impfdatum
30.08.2022
Beginn
30.08.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
OT / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
No adverse event Product administered to patient of inappropriate age

Symptomtext

Patient under age 65 administered Fluzone HD in error with no reported adverse event; Initial information received on 30-Aug-2022 regarding an unsolicited valid non-serious case received from a pharmacist. This case involves a 28 years old female patient who was under age 65 administered fluzone hd in error with no reported adverse event ,while receiving vaccine INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE [FLUZONE HIGH-DOSE QUADRIVALENT]. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On 30-Aug-2022, the patient received a total dose of suspect INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE lot UJN04AA and expiration date:30-Jun-2023 at a dose of 0.7ml via intramuscular route in the deltoid nos for immunization. On 30-Aug-2022(latency: same day) , the patient was under age 65 administered fluzone hd in error with no reported adverse event (product administered to patient of inappropriate age) following the administration. Action taken :not applicable. It was not reported if the patient received a corrective treatment for the event . Outcome: Unknown This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.

Weitere VAERSDATA-Felder
Praegender Schweregrund
No adverse event
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-